

DAFTAR PUSTAKA

- Alshamiri, M., Ghanaim, M. M. A., Barter, P., Chang, K. C., Li, J. J., Matawaran, B. J., Santoso, A., Shaheen, S., Suastika, K., Thongtang, N., & Yusof, A. K. M. (2018). Expert opinion on the applicability of dyslipidemia guidelines in Asia and the middle east. *International Journal of General Medicine*, 11, 313–322. <https://doi.org/10.2147/IJGM.S160555>
- Alsharif, N. Z., & Faulkner, M. A. (2020). Implementation of the Pharmacists' Patient Care Process in a Medicinal Chemistry Course. *American Journal of Pharmaceutical Education*, 84(2), 202–212. <https://doi.org/10.5688/ajpe7556>
- Althanoon, Z., Faisal, I. M., Ahmad, A. A., Merkhan, M. M., & Merkhan Pharmacology, M. M. (2020). Pharmacological Aspects of Statins Are Relevant to Their Structural and Physicochemical Properties. In *Systematic Reviews in Pharmacy* (Vol. 11, Issue 7).
- Baxter, K. (2010). *Stockley's drug interactions*. 9th Edition. London: Pharmaceutical Press.
- Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., Nordestgaard, B. G., Watts, G. F., Bruckert, E., Fazio, S., Ference, B. A., Graham, I., Horton, J. D., Landmesser, U., Laufs, U., ... Ginsberg, H. N. (2020). Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, 41(24), 2313–2330. <https://doi.org/10.1093/eurheartj/ehz962>
- Cerqueira, N. M. F. S. A., Oliveira, E. F., Gesto, D. S., Santos-Martins, D., Moreira, C., Moorthy, H. N., Ramos, M. J., & Fernandes, P. A. (2016). Cholesterol Biosynthesis: A Mechanistic Overview. *Biochemistry*, 55(39), 5483–5506. <https://doi.org/10.1021/acs.biochem.6b00342>
- Dorotea, D., Ayumuyas, N. P., Suprpti, B., & Wibisono, S. (2013). The Comparison of Simvastatin and Atorvastatin Efficacy in Lowering Lipid Profile and Apolipoprotein-B of Diabetic Dyslipidemia Patient. *Folia Medica Indonesiana*, 49(3), 139–145.

- Farnier, M., Portal, J. J., & Maigret, P. (2000). Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. *Journal of Cardiovascular Pharmacology and Therapeutics*, 5(1), 27–32. <https://doi.org/10.1177/107424840000500104>
- Feely, J., & O'Connor, P. (1991). Effects of HMG CoA Reductase Inhibitors on Warfarin Binding. *Drug Invest*, 3(5), 315–316.
- Fernandes, J. P. S. (2018). The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education. *American Journal of Pharmaceutical Education*, 82(2), 6083. <https://doi.org/10.5688/ajpe6083>
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCN A Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. In *Circulation* (Vol. 139, Issue 25, pp. E1082–E1143). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIR.0000000000000625>
- Halava, H., Helin-Salmivaara, A., Junnila, J., & Huupponen, R. (2009). Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. *European Journal of Clinical Pharmacology*, 65(9), 927–933. <https://doi.org/10.1007/s00228-009-0664-1>
- Handayani, M., & Simatupang, A. (2019). Penggunaan Statin pada Pasien Hiperkolesterolemia. *Majalah Kedokteran UKI*, 35(3), 96–103.
- Karr, S. (2017). Epidemiology and management of hyperlipidemia. In *The American journal of managed care* (Vol. 23, Issue 9). www.ajmc.com
- Kostis, W. J., Cheng, J. Q., Dobrzynski, J. M., Cabrera, J., & Kostis, J. B. (2012). Meta-analysis of statin effects in women versus men. *Journal of the American College of Cardiology*, 59(6), 572–582. <https://doi.org/10.1016/j.jacc.2011.09.067>
- Moorthy, N. S. H. N., Cerqueira, N. M. F. S. A., Ramos, M. J., & Fernandes, P. A. (2015). Ligand based analysis on HMG-CoA reductase inhibitors. *Chemometrics and Intelligent Laboratory Systems*, 140, 102–116. <https://doi.org/10.1016/j.chemolab.2014.11.009>

- Murphy, C., Deplazes, E., Cranfield, C. G., & Garcia, A. (2020). The role of structure and biophysical properties in the pleiotropic effects of statins. In *International Journal of Molecular Sciences* (Vol. 21, Issue 22, pp. 1–29). MDPI AG. <https://doi.org/10.3390/ijms21228745>
- Nouh, F., Omar, M., & Younis, M. (2019). Risk Factors and Management of Hyperlipidemia (Review). *Asian Journal of Cardiology Research*, 2(1), 1–10. <https://doi.org/10.9734/AJCR/2019/45449>
- Ohsfeldt, R. L., Gandhi, S. K., Fox, K. M., Stacy, T. A., & McKenney, J. M. (2006). Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. In *American Journal of Managed Care* (Vol. 12).
- Pose, E., Trebicka, J., Mookerjee, R. P., Angeli, P., & Ginès, P. (2019). Statins: Old drugs as new therapy for liver diseases? In *Journal of Hepatology* (Vol. 70, Issue 1, pp. 194–202). Elsevier B.V. <https://doi.org/10.1016/j.jhep.2018.07.019>
- Prianwari, C., & Syafril, S. (2020). Relationship Between Triglycerides And Glucose Index (TyG) And Lipid Profile In Patients With Dyslipidemia Treated With Bay Leaf Extract (*Syzygium Polyanthum* (Wight) Walp). *Journal of Endocrinology, Tropical Medicine, and Infectious Disease*, 2(4), 177–182. <https://doi.org/10.32734/jetromi.v2i4.4778>
- Roche, V. F. (2005). Antihyperlipidemic Statins: A Self-Contained, Clinically Relevant Medicinal Chemistry Lesson. *American Journal of Pharmaceutical Education*, 69(4), 77. <https://doi.org/10.5688/aj690477>
- Schachter, M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. In *Fundamental and Clinical Pharmacology* (Vol. 19, Issue 1, pp. 117–125). <https://doi.org/10.1111/j.1472-8206.2004.00299.x>
- Shuhaili, M. F. R. M. A., Samsudin, I. N., Stanslas, J., Hasan, S., & Thambiah, S. C. (2017). Effects of different types of statins on lipid profile: A perspective on asians. In *International Journal of Endocrinology and Metabolism* (Vol. 15, Issue 2). Kowsar Medical Publishing Company. <https://doi.org/10.5812/ijem.43319>
- Silva Afonso, M., Marcondes Machado, R., Ferrari Lavrador, M. S., Rocha Quintao, E. C., Moore, K. J., & Lottenberg, A. M. (2018). Molecular pathways underlying cholesterol homeostasis. In *Nutrients* (Vol. 10, Issue 6). MDPI AG. <https://doi.org/10.3390/nu10060760>

- Soliman, G. A. (2018). Dietary cholesterol and the lack of evidence in cardiovascular disease. In *Nutrients* (Vol. 10, Issue 6). MDPI AG. <https://doi.org/10.3390/nu10060780>
- Trapani, L., Segatto, M., & Pallottini, V. (2012). Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station.” *World Journal of Hepatology*, 4(6), 184–190. <https://doi.org/10.4254/wjh.v4.i6.184>
- Ward, N. C., Watts, G. F., & Eckel, R. H. (2019). Statin Toxicity: Mechanistic Insights and Clinical Implications. In *Circulation Research* (Vol. 124, Issue 2, pp. 328–350). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIRCRESAHA.118.312782>
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2015). *Pharmacotherapy handbook* (9th edition). New York : McGraw-Hill
- Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016). Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association. *Circulation*, 134(21), e468–e495. <https://doi.org/10.1161/CIR.0000000000000456>
- Young, I. S., & Gaw, A. (2012). Lipid metabolism. *Current Opinion in Lipidology*, 23(5), 503–504. <https://doi.org/10.1097/MOL.0b013e328358247d>
- Yuan, Y., Chen, W., Luo, L., & Xu, C. (2021). Dyslipidemia: Causes, Symptoms and Treatment. *International Journal of Trend in Scientific Research and Development*, 5(2), 1013–1016.
- Zhang, X., Xing, L., Jia, X., Pang, X., Xiang, Q., Zhao, X., Ma, L., Liu, Z., Hu, K., Wang, Z., & Cui, Y. (2020). Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. In *Cardiovascular Therapeutics* (Vol. 2020). Hindawi Limited. <https://doi.org/10.1155/2020/3987065>

LAMPIRAN

Lampiran 1. Kode Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDINI SUEHROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
Jl. PERKOTA KEMERDEKAAN KAMPUS TAMALAKKA KM.10 MAKASSAR 90240.
Contact Person dr. Agusssalim Bukhari, M.Med,Ph.D.,Sp.GK, Telp. 08223990308, 0411 3080002, Fax : 0411 301432

REKOMENDASI PERSETUJUAN ETIK
Nomor : 319/UN4.6.4.5.11/PP/16/2021

Tanggal: 4 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21050285	No Sponsor Protokol	
Peneliti Utama	Wenry Deston Latif, S.Farm, Apt	Sponsor	
Judul Peneliti	Evaluasi Terapi Berbasis Struktur Dari Senyawa Golongan Statin Terhadap Profil Lipid Darah : Studi Kasus di ICU Ramah-Sakit Makassar		
No Versi Protokol	1	Tanggal Versi	3 Mei 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 4 Mei 2021 sampai 4 Mei 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Saryani As'ad, M.Sc.,Sp.GK (K)		
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agusssalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		

Kewajiban Peneliti Utama:

- Menyerahkan Amendemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapinya dalam 7 hari dan Laporan SUSAH dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang diertapi (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Dokumentasi penelitian



Lampiran 3. Analisis statistik

Frequency

Jenis Obat Statin

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	simvastatin	32	45.1	45.1	45.1
	atorvastatin	39	54.9	54.9	100.0
	Total	71	100.0	100.0	

Pekerjaan

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	Tidak bekerja	39	54.9	54.9	54.9
	Bekerja	32	45.1	45.1	100.0
	Total	71	100.0	100.0	

Jenis Kelamin

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	laki-laki	36	50.7	50.7	50.7
	perempuan	35	49.3	49.3	100.0
	Total	71	100.0	100.0	

Tekanan Darah awal

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	normal	21	29.6	29.6	29.6
	pra hipertensi	13	18.3	18.3	47.9
	hipertensi stage 1	16	22.5	22.5	70.4
	hipertensi stage 2	21	29.6	29.6	100.0
	Total	71	100.0	100.0	

Tekanan Darah akhir

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	normal	28	39.4	39.4	39.4
	pra hipertensi	25	35.2	35.2	74.6
	hipertensi stage 1	13	18.3	18.3	93.0

hipertensi stage 2	5	7.0	7.0	100.0
Total	71	100.0	100.0	

status merokok

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	tidak merokok	58	81.7	81.7	81.7
	merokok	13	18.3	18.3	100.0
	Total	71	100.0	100.0	

minum alkohol

		Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	tidak minum alkohol	68	95.8	95.8	95.8
	minum alkohol	3	4.2	4.2	100.0
	Total	71	100.0	100.0	

Explore

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Lama rawat	.197	71	.000	.869	71	.000

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
Lama rawat	Mean	6.86	.314	
	95% Confidence Interval for Mean	Lower Bound	6.23	
		Upper Bound	7.48	
	5% Trimmed Mean	6.65		
	Median	6.00		
	Variance	6.980		
	Std. Deviation	2.642		
	Minimum	3		
	Maximum	15		
	Range	12		
	Interquartile Range	3		

Skewness	1.290	.285
Kurtosis	1.410	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Umu r	.054	71	.200	.992	71	.938

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error
Umu r	Mean	62.92	1.296
	95% Confidence Interval for Mean	Lower Bound Upper Bound	
		60.33 65.50	
	5% Trimmed Mean	63.04	
	Median	63.00	
	Variance	119.250	
	Std. Deviation	10.920	
	Minimum	35	
	Maximum	89	
	Range	54	
	Interquartile Range	15	
	Skewness	-.083	.285
	Kurtosis	-.051	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
LDL awal	.186	71	.000	.661	71	.000

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error
LDL awal	Mean	162.97	11.304
	95% Confidence Interval Lower Bound	140.43	

for Mean	Upper Bound	185.52	
5% Trimmed Mean		151.08	
Median		136.00	
Variance		9072.85	
		6	
Std. Deviation		95.252	
Minimum		52	
Maximum		645	
Range		593	
Interquartile Range		74	
Skewness		3.423	.285
Kurtosis		14.972	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
HDL awal	.133	71	.003	.872	71	.000

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
HDL awal	Mean	65.49	3.101	
	95% Confidence Interval for Mean	Lower Bound	59.31	
		Upper Bound	71.68	
	5% Trimmed Mean	63.08		
	Median	64.00		
	Variance	682.711		
	Std. Deviation	26.129		
	Minimum	31		
	Maximum	183		
	Range	152		
	Interquartile Range	30		
	Skewness	1.722	.285	
	Kurtosis	5.172	.563	

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TC awal	.209	71	.000	.633	71	.000

a. Lilliefors Significance Correction

Descriptives

			Statistic	Std. Error
TC awal	Mean		218.82	9.521
	95% Confidence Interval for Mean	Lower Bound	199.83	
		Upper Bound	237.81	
	5% Trimmed Mean		209.97	
	Median		214.00	
	Variance		6435.86	
			6	
	Std. Deviation		80.224	
	Minimum		124	
	Maximum		752	
	Range		628	
	Interquartile Range		56	
	Skewness		4.404	.285
	Kurtosis		27.812	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TG awal	.168	71	.000	.872	71	.000

a. Lilliefors Significance Correction

Descriptives

			Statistic	Std. Error
TG awal	Mean		159.82	8.225
	95% Confidence Interval for Mean	Lower Bound	143.41	
		Upper Bound	176.22	
	5% Trimmed Mean		153.75	
	Median		152.00	
	Variance		4802.89	
			5	
	Std. Deviation		69.303	
Minimum		50		

Maximum	426	
Range	376	
Interquartile Range	62	
Skewness	1.592	.285
Kurtosis	3.318	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
LDL akhir	.183	71	.000	.682	71	.000

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error
LDL akhir	Mean	149.59	10.202
	95% Confidence Interval for Mean	Lower Bound Upper Bound	129.24 169.94
	5% Trimmed Mean	138.77	
	Median	124.00	
	Variance	7390.38	8
	Std. Deviation	85.967	
	Minimum	38	
	Maximum	631	
	Range	593	
	Interquartile Range	71	
	Skewness	3.393	.285
	Kurtosis	15.641	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
HDL akhir	.097	71	.093	.973	71	.129

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std.
--	--	-----------	------

			Error	
HDL akhir	Mean		72.76	1.997
	95% Confidence Interval for Mean	Lower Bound	68.78	
		Upper Bound	76.74	
	5% Trimmed Mean		72.31	
	Median		75.00	
	Variance		283.128	
	Std. Deviation		16.826	
	Minimum		43	
	Maximum		118	
	Range		75	
	Interquartile Range		24	
	Skewness		.247	.285
	Kurtosis		-.137	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TC akhir	.165	71	.000	.856	71	.000

a. Lilliefors Significance Correction

Descriptives

			Statistic	Std. Error
TC akhir	Mean		192.45	6.609
	95% Confidence Interval for Mean	Lower Bound	179.27	
		Upper Bound	205.63	
	5% Trimmed Mean		187.96	
	Median		188.00	
	Variance		3100.73	
			7	
	Std. Deviation		55.684	
	Minimum		107	
	Maximum		468	
	Range		361	
	Interquartile Range		52	
	Skewness		2.024	.285
	Kurtosis		7.832	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TG akhir	.129	71	.005	.950	71	.007

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
TG akhir	Mean	124.65	5.709	
	95% Confidence Interval for Mean	Lower Bound	113.26	
		Upper Bound	136.03	
	5% Trimmed Mean	122.74		
	Median	119.00		
	Variance	2313.889		
	Std. Deviation	48.103		
	Minimum	29		
	Maximum	275		
	Range	246		
	Interquartile Range	51		
	Skewness	.807	.285	
	Kurtosis	.788	.563	

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Berat badan	.074	71	.200	.979	71	.296

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
Berat badan	Mean	59.86	1.032	
	95% Confidence Interval for Mean	Lower Bound	57.80	
		Upper Bound	61.92	
	5% Trimmed Mean	59.66		
	Median	60.00		

Variance	75.551	
Std. Deviation	8.692	
Minimum	43	
Maximum	80	
Range	37	
Interquartile Range	11	
Skewness	.315	.285
Kurtosis	-.330	.563

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Tinggi Badan	.106	71	.045	.969	71	.073

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
Tinggi Badan	Mean	159.66	.748	
	95% Confidence Interval for Mean	Lower Bound	158.17	
		Upper Bound	161.15	
	5% Trimmed Mean	159.67		
	Median	160.00		
	Variance	39.770		
	Std. Deviation	6.306		
	Minimum	147		
	Maximum	172		
	Range	25		
	Interquartile Range	10		
	Skewness	-.024	.285	
	Kurtosis	-.976	.563	

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Obat	.162	71	.000	.939	71	.002

lainnya

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
Obat lainnya	Mean	7.69	.254	
	95% Confidence Interval for Mean	Lower Bound	7.18	
		Upper Bound	8.20	
	5% Trimmed Mean	7.61		
	Median	7.00		
	Variance	4.588		
	Std. Deviation	2.142		
	Minimum	4		
	Maximum	14		
	Range	10		
	Interquartile Range	3		
	Skewness	.578	.285	
	Kurtosis	-.225	.563	

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Komorbidity	.321	71	.000	.835	71	.000

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
Komorbidity	Mean	3.15	.098	
	95% Confidence Interval for Mean	Lower Bound	2.96	
		Upper Bound	3.35	
	5% Trimmed Mean	3.12		
	Median	3.00		
	Variance	.676		

Std. Deviation	.822	
Minimum	1	
Maximum	6	
Range	5	
Interquartile Range	1	
Skewness	.655	.285
Kurtosis	1.872	.563

Split File Frequency

			Pekerjaan			
Jenis Obat Statin			Frequenc y	Percent	Valid Percent	Cumulative Percent
Simvastati n	Vali d	Tidak bekerja	19	59.4	59.4	59.4
		bekerja	13	40.6	40.6	100.0
		Total	32	100.0	100.0	
Atorvastati n	Vali d	Tidak bekerja	20	51.3	51.3	51.3
		bekerja	19	48.7	48.7	100.0
		Total	39	100.0	100.0	

			Jenis Kelamin			
Jenis Obat Statin			Frequenc y	Percent	Valid Percent	Cumulative Percent
Simvastati n	Vali d	laki-laki	14	43.8	43.8	43.8
		perempuan	18	56.3	56.3	100.0
		Total	32	100.0	100.0	
Atorvastati n	Vali d	laki-laki	22	56.4	56.4	56.4
		perempuan	17	43.6	43.6	100.0
		Total	39	100.0	100.0	

			Tekanan Darah awal			
Jenis Obat Statin			Frequenc y	Percent	Valid Percent	Cumulative Percent

Simvastatin	Valid	normal	5	15.6	15.6	15.6
		pra hipertensi	6	18.8	18.8	34.4
		hipertensi stage 1	11	34.4	34.4	68.8
		hipertensi stage 2	10	31.3	31.3	100.0
		Total	32	100.0	100.0	
Atorvastatin	Valid	normal	16	41.0	41.0	41.0
		pra hipertensi	7	17.9	17.9	59.0
		hipertensi stage 1	5	12.8	12.8	71.8
		hipertensi stage 2	11	28.2	28.2	100.0
		Total	39	100.0	100.0	

status merokok

Jenis Obat Statin			Frequency	Percent	Valid Percent	Cumulative Percent
Simvastatin	Valid	tidak merokok	28	87.5	87.5	87.5
		merokok	4	12.5	12.5	100.0
		Total	32	100.0	100.0	
Atorvastatin	Valid	tidak merokok	30	76.9	76.9	76.9
		merokok	9	23.1	23.1	100.0
		Total	39	100.0	100.0	

minum alkohol

Jenis Obat Statin			Frequency	Percent	Valid Percent	Cumulative Percent
Simvastatin	Valid	tidak minum alkohol	31	96.9	96.9	96.9
		minum alkohol	1	3.1	3.1	100.0
		Total	32	100.0	100.0	
Atorvastatin	Valid	tidak minum alkohol	37	94.9	94.9	94.9
		minum alkohol	2	5.1	5.1	100.0
		Total	39	100.0	100.0	

Split File Explore

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	Umur	.127	32	.200	.969	32	.461
Atorvastatin	Umur	.122	39	.148	.952	39	.099

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error	
simvastatin	Umu r	Mean		62.97	2.211	
		95% Confidence Interval for Mean		Lower Bound	58.46	
				Upper Bound	67.48	
		5% Trimmed Mean			63.06	
		Median			63.00	
		Variance			156.418	
		Std. Deviation			12.507	
		Minimum			35	
		Maximum			89	
		Range			54	
		Interquartile Range			11	
		Skewness			-.109	.414
		Kurtosis			.287	.809
		atorvastatin	Umu r	Mean		62.87
95% Confidence Interval for Mean				Lower Bound	59.76	
				Upper Bound	65.98	
5% Trimmed Mean					62.94	
Median					64.00	
Variance					92.062	
Std. Deviation					9.595	
Minimum					46	
Maximum					79	
Range					33	
Interquartile Range					15	
Skewness					-.047	.378
Kurtosis					-1.192	.741

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	Berat badan	.122	32	.200*	.961	32	.286
atorvastatin	Berat badan	.091	39	.200*	.982	39	.791

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error	
simvastatin	Berat badan	Mean		60.94	1.598	
		95% Confidence Interval for Mean		Lower Bound	57.68	
				Upper Bound	64.20	
		5% Trimmed Mean		60.72		
		Median		60.00		
		Variance		81.738		
		Std. Deviation		9.041		
		Minimum		45		
		Maximum		80		
		Range		35		
		Interquartile Range		11		
		Skewness		.447	.414	
		Kurtosis		-.422	.809	
		Atorvastatin	Berat badan	Mean		58.97
95% Confidence Interval for Mean				Lower Bound	56.25	
				Upper Bound	61.70	
5% Trimmed Mean				58.80		
Median				60.00		
Variance				70.710		
Std. Deviation				8.409		
Minimum				43		
Maximum				78		
Range				35		
Interquartile Range				12		
Skewness				.159	.378	
Kurtosis				-.325	.741	

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	Tinggi Badan	.112	32	.200*	.980	32	.787
Atorvastatin	Tinggi Badan	.155	39	.019	.948	39	.068

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error
simvastatin	Tinggi Badan	Mean		158.44	1.024
		95% Confidence Interval for Mean	Lower Bound	156.35	
			Upper Bound	160.53	
		5% Trimmed Mean		158.43	
		Median		158.50	
		Variance		33.544	
		Std. Deviation		5.792	
		Minimum		147	
		Maximum		170	
		Range		23	
		Interquartile Range		9	
		Skewness		.134	.414
		Kurtosis		-.537	.809
		atorvastatin	Tinggi Badan	Mean	
95% Confidence Interval for Mean	Lower Bound			158.53	
	Upper Bound			162.81	
5% Trimmed Mean				160.71	
Median				160.00	
Variance				43.596	
Std. Deviation				6.603	
Minimum				149	
Maximum				172	
Range				23	
Interquartile Range				10	
Skewness				-.224	.378
Kurtosis				-1.097	.741

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	Obat lainnya	.182	32	.009	.945	32	.103
atorvastatin	Obat lainnya	.147	39	.034	.919	39	.008

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error	
simvastatin	Obat lainnya	Mean		7.63	.364	
		95% Confidence Interval for Mean		Lower Bound	6.88	
				Upper Bound	8.37	
		5% Trimmed Mean		7.58		
		Median		7.00		
		Variance		4.242		
		Std. Deviation		2.060		
		Minimum		4		
		Maximum		12		
		Range		8		
		Interquartile Range		3		
		Skewness		.448	.414	
		Kurtosis		-.644	.809	
		Atorvastatin	Obat lainnya	Mean		7.74
95% Confidence Interval for Mean				Lower Bound	7.02	
				Upper Bound	8.47	
5% Trimmed Mean				7.63		
Median				7.00		
Variance				4.985		
Std. Deviation				2.233		
Minimum				5		
Maximum				14		
Range				9		
Interquartile Range				3		
Skewness				.669	.378	
Kurtosis				.062	.741	

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	Lama rawat	.183	32	.008	.868	32	.001
Atorvastatin	Lama rawat	.208	39	.000	.865	39	.000

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error
simvastatin	Lama rawat	Mean		6.97	.483
		95% Confidence Interval for Mean	Lower Bound	5.98	
			Upper Bound	7.95	
		5% Trimmed Mean		6.76	
		Median		6.00	
		Variance		7.451	
		Std. Deviation		2.730	
		Minimum		4	
		Maximum		14	
		Range		10	
		Interquartile Range		3	
		Skewness		1.182	.414
		Kurtosis		.913	.809
		atorvastatin	Lama rawat	Mean	
95% Confidence Interval for Mean	Lower Bound			5.93	
	Upper Bound			7.61	
5% Trimmed Mean				6.55	
Median				6.00	
Variance				6.761	
Std. Deviation				2.600	
Minimum				3	
Maximum				15	
Range				12	
Interquartile Range				3	
Skewness				1.441	.378
Kurtosis				2.290	.741

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	Komorbidity	.298	32	.000	.848	32	.000
atorvastatin	Komorbidity	.344	39	.000	.794	39	.000

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error
simvastatin	Komorbiditas	Mean		3.28	.136
		95% Confidence Interval for Mean	Lower Bound	3.00	
			Upper Bound	3.56	
		5% Trimmed Mean		3.26	
		Median		3.00	
		Variance		.596	
		Std. Deviation		.772	
		Minimum		2	
		Maximum		5	
		Range		3	
		Interquartile Range		1	
		Skewness		.352	.414
		Kurtosis		.077	.809
		Atorvastatin	Komorbiditas	Mean	
95% Confidence Interval for Mean	Lower Bound			2.77	
	Upper Bound			3.33	
5% Trimmed Mean				3.00	
Median				3.00	
Variance				.734	
Std. Deviation				.857	
Minimum				1	
Maximum				6	
Range				5	
Interquartile Range				0	
Skewness				.957	.378
Kurtosis				3.559	.741

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	LDL awal	.194	32	.004	.674	32	.000
Atorvastatin	LDL awal	.193	39	.001	.650	39	.000

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin	Statistic	Std.
-------------------	-----------	------

					Error		
simvastatin	LDL awal	Mean			161.56	17.433	
		95% Confidence Interval for Mean	Lower Bound			126.01	
			Upper Bound			197.12	
		5% Trimmed Mean			148.51		
		Median			131.50		
		Variance			9724.57		
					7		
		Std. Deviation			98.613		
		Minimum			52		
		Maximum			611		
		Range			559		
		Interquartile Range			84		
		Skewness			3.282	.414	
		Kurtosis			13.940	.809	
atorvastatin	LDL awal	Mean			164.13	15.002	
		95% Confidence Interval for Mean	Lower Bound			133.76	
			Upper Bound			194.50	
		5% Trimmed Mean			153.76		
		Median			146.00		
		Variance			8776.90		
					4		
		Std. Deviation			93.685		
		Minimum			54		
		Maximum			645		
		Range			591		
		Interquartile Range			73		
		Skewness			3.707	.378	
		Kurtosis			18.384	.741	

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	HDL awal	.107	32	.200	.920	32	.021
atorvastatin	HDL awal	.207	39	.000	.847	39	.000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin				Statistic	Std. Error
simvastatin	HDL awal	Mean		63.19	3.752
		95% Confidence Interval for Mean	Lower Bound	55.53	
			Upper Bound	70.84	
		5% Trimmed Mean		61.88	
		Median		64.00	
		Variance		450.544	
		Std. Deviation		21.226	
		Minimum		32	
		Maximum		133	
		Range		101	
		Interquartile Range		30	
		Skewness		.980	.414
		Kurtosis		2.190	.809
		Atorvastatin	HDL awal	Mean	
95% Confidence Interval for Mean	Lower Bound			57.76	
	Upper Bound			77.01	
5% Trimmed Mean				64.50	
Median				64.00	
Variance				881.927	
Std. Deviation				29.697	
Minimum				31	
Maximum				183	
Range				152	
Interquartile Range				28	
Skewness				1.826	.378
Kurtosis				5.008	.741

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	TC awal	.245	32	.000	.599	32	.000
Atorvastatin	TC awal	.167	39	.007	.923	39	.011

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin	Statistic	Std.
-------------------	-----------	------

				Error			
simvastatin	TC awal	Mean		229.69	19.048		
		95% Confidence Interval for Mean	Lower Bound	190.84			
			Upper Bound	268.54			
		5% Trimmed Mean		214.15			
		Median		214.50			
		Variance		11610.738			
		Std. Deviation		107.753			
		Minimum		124			
		Maximum		752			
		Range		628			
		Interquartile Range		72			
		Skewness		3.890	.414		
		Kurtosis		18.518	.809		
		atorvastatin	TC awal	Mean		209.90	7.515
				95% Confidence Interval for Mean	Lower Bound	194.68	
Upper Bound	225.11						
5% Trimmed Mean				207.14			
Median				213.00			
Variance				2202.463			
Std. Deviation				46.930			
Minimum				126			
Maximum				362			
Range				236			
Interquartile Range				46			
Skewness				.997	.378		
Kurtosis				2.289	.741		

Tests of Normality

Jenis Obat Statin		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
simvastatin	TG awal	.133	32	.162	.856	32	.001
atorvastatin	TG awal	.185	39	.002	.899	39	.002

a. Lilliefors Significance Correction

Descriptives

Jenis Obat Statin	Statistic	Std. Error
-------------------	-----------	---------------

simvastatin	TG awal	Mean		144.44	9.396
		95% Confidence Interval for Mean	Lower Bound	125.27	
			Upper Bound	163.60	
		5% Trimmed Mean		140.02	
		Median		134.00	
		Variance		2825.09	
		Std. Deviation		53.152	
		Minimum		61	
		Maximum		349	
		Range		288	
		Interquartile Range		64	
		Skewness		1.851	.414
		Kurtosis		5.981	.809
		Atorvastati n	TG awal	Mean	
95% Confidence Interval for Mean	Lower Bound			146.95	
	Upper Bound			197.92	
5% Trimmed Mean				166.61	
Median				157.00	
Variance				6180.14	
Std. Deviation				78.614	
Minimum				50	
Maximum				426	
Range				376	
Interquartile Range				75	
Skewness				1.323	.378
Kurtosis				2.108	.741

Crosstabs

Jenis Obat Statin * Pekerjaan Cross Tabulation

Count

		Pekerjaan		Total
		Tidak bekerja	bekerja	
Jenis Obat Statin	simvastatin	19	13	32
	atorvastati n	20	19	39
Total		39	32	71

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.465 ^a	1	.495		
Continuity Correction	.196	1	.658		
Likelihood Ratio	.466	1	.495		
Fisher's Exact Test				.632	.330
Linear-by-Linear Association	.458	1	.498		
N of Valid Cases	71				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 14.42.

b. Computed only for a 2x2 table

Jenis Obat Statin * Jenis Kelamin Cross Tabulation

Count

		Jenis Kelamin		Total
		laki-laki	perempuan	
Jenis Obat Statin	simvastatin	14	18	32
	atorvastatin	22	17	39
Total		36	35	71

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.127 ^a	1	.288		
Continuity Correction	.678	1	.410		
Likelihood Ratio	1.130	1	.288		
Fisher's Exact Test				.344	.205
Linear-by-Linear Association	1.111	1	.292		
N of Valid Cases	71				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 15.77.

b. Computed only for a 2x2 table

Jenis Obat Statin * Tekanan Darah awal Crosstabulation

Count

Tekanan Darah awal

Total

		normal	pra hipertensi	hipertensi stage 1	hipertensi stage 2	
Jenis Obat Statin	simvastatin	5	6	11	10	32
	atorvastatin	16	7	5	11	39
Total		21	13	16	21	71

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	7.519 ^a	3	.057
Likelihood Ratio	7.799	3	.050
Linear-by-Linear Association	3.404	1	.065
N of Valid Cases	71		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.86.

Jenis Obat Statin * status merokok Cross Tabulation

Count

		status merokok		Total
		tidak merokok	merokok	
Jenis Obat Statin	simvastatin	28	4	32
	atorvastatin	30	9	39
Total		58	13	71

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.315 ^a	1	.252		
Continuity Correction	.703	1	.402		
Likelihood Ratio	1.351	1	.245		
Fisher's Exact Test				.358	.202
Linear-by-Linear Association	1.296	1	.255		
N of Valid Cases	71				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.86.

b. Computed only for a 2x2 table

Jenis Obat Statin * minum alkohol Cross Tabulation

Count

		minum alkohol		Total
		tidak minum alkohol	minum alkohol	
Jenis Obat Statin	simvastatin	31	1	32
	atorvastatin	37	2	39
Total		68	3	71

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.174 ^a	1	.676		
Continuity Correction	.000	1	1.000		
Likelihood Ratio	.179	1	.673		
Fisher's Exact Test				1.000	.575
Linear-by-Linear Association	.172	1	.678		
N of Valid Cases	71				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.35.

b. Computed only for a 2x2 table

Mann-Whitney Test

Test Statistics

	Tinggi Badan
Mann-Whitney U	495.500
Wilcoxon W	1023.500
Z	-1.490
Asymp. Sig. (2-tailed)	.136

a. Grouping Variable: Jenis Obat Statin

Test Statistics^a

Lama rawat

Mann-Whitney U	604.000
Wilcoxon W	1384.000
Z	-.234
Asymp. Sig. (2-tailed)	.815

a. Grouping Variable: Jenis Obat
Statin

Test Statistics^aObat
lainnya

Mann-Whitney U	612.500
Wilcoxon W	1140.500
Z	-.134
Asymp. Sig. (2-tailed)	.893

a. Grouping Variable: Jenis Obat
Statin

Test Statistics^a

Komorbiditas

Mann-Whitney U	515.000
Wilcoxon W	1295.000
Z	-1.424
Asymp. Sig. (2-tailed)	.154

a. Grouping Variable: Jenis Obat
Statin

Test Statistics^aLDL
awal

Mann-Whitney U	571.000
Wilcoxon W	1099.000
Z	-.613
Asymp. Sig. (2-tailed)	.540

a. Grouping Variable: Jenis Obat
Statin

Test Statistics^aHDL
awal

Mann-Whitney U	623.500
Wilcoxon W	1151.500
Z	-.006

Asymp. Sig. (2-tailed)	.995
------------------------	------

a. Grouping Variable: Jenis Obat
Statin

Test Statistics^a

	TC awal
Mann-Whitney U	574.500
Wilcoxon W	1354.50
	0
Z	-.572
Asymp. Sig. (2-tailed)	.567

a. Grouping Variable: Jenis Obat
Statin

Test Statistics^a

	TG awal
Mann-Whitney U	484.000
Wilcoxon W	1012.00
	0
Z	-1.618
Asymp. Sig. (2-tailed)	.106

a. Grouping Variable: Jenis Obat
Statin

Independent sample t test

Group Statistics

	Jenis Obat Statin	N	Mean	Std. Deviation	Std. Error Mean
Umur	Simvastatin	32	62.97	12.507	2.211
	Atorvastatin	39	62.87	9.595	1.536

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means					95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Umur	Equal variances assumed	.424	.517	.037	69	.971	.097	2.623	-5.137	5.331
	Equal variances not assumed			.036	57.274	.971	.097	2.692	-5.294	5.488

Group Statistics

	Jenis Obat Statin	N	Mean	Std. Deviation	Std. Error Mean
Berat badan	simvastatin	32	60.94	9.041	1.598
	atorvastatin	39	58.97	8.409	1.347

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means					95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Berat badan	Equal variances assumed	.414	.522	.946	69	.347	1.963	2.075	-2.176	6.102
	Equal variances not assumed			.939	64.228	.351	1.963	2.090	-2.211	6.138

Analisis univariat

Estimates

Dependent Variable: LDL akhir

Jenis Obat Statin	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
simvastatin	142.938	15.269	112.478	173.397
atorvastatin	155.051	13.831	127.460	182.643

Pairwise Comparisons

Dependent Variable: LDL akhir

(I) Jenis Obat Statin	(J) Jenis Obat Statin	Mean Difference (I-J)	Std. Error	Sig. ^a	95% Confidence Interval for Difference ^a	
					Lower Bound	Upper Bound
simvastatin	atorvastatin	-12.114	20.601	.558	-53.212	28.985
atorvastatin	simvastatin	12.114	20.601	.558	-28.985	53.212

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Estimates

Dependent Variable: HDL akhir

Jenis Obat Statin	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
simvastatin	72.531	2.996	66.555	78.508
atorvastatin	72.949	2.714	67.535	78.362

Pairwise Comparisons

Dependent Variable: HDL akhir

(I) Jenis Obat Statin	(J) Jenis Obat Statin	Mean Difference (I-J)	Std. Error	Sig. ^a	95% Confidence Interval for Difference ^a	
					Lower Bound	Upper Bound
simvastatin	atorvastatin	-.417	4.042	.918	-8.481	7.646
atorvastatin	simvastatin	.417	4.042	.918	-7.646	8.481

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Estimates

Dependent Variable: TC akhir

Jenis Obat Statin	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
simvastatin	198.875	9.860	179.205	218.545
atorvastatin	187.179	8.931	169.362	204.997

Pairwise Comparisons

Dependent Variable: TC akhir

(I) Jenis Obat Statin	(J) Jenis Obat Statin	Mean Difference (I-J)	Std. Error	Sig. ^a	95% Confidence Interval for Difference ^a	
					Lower Bound	Upper Bound
simvastatin	atorvastatin	11.696	13.303	.382	-14.844	38.235
Atorvastatin	simvastatin	-11.696	13.303	.382	-38.235	14.844

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Estimates

Dependent Variable: TG akhir

Jenis Obat Statin	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
simvastatin	127.406	8.553	110.343	144.469
atorvastatin	122.385	7.748	106.929	137.841

Pairwise Comparisons

Dependent Variable: TG akhir

(I) Jenis Obat Statin	(J) Jenis Obat Statin	Mean Difference (I-J)	Std. Error	Sig. ^a	95% Confidence Interval for Difference	
					Lower Bound	Upper Bound
simvastatin	atorvastatin	5.022	11.540	.665	-18.001	28.044
atorvastatin	simvastatin	-5.022	11.540	.665	-28.044	18.001

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.